Project Grant R21HL181601
Award Date 8/15/26
Completion Date 7/31/28
Dollars Obligated $242K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $593,663 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate thrombolysis resistance in acute ischemic stroke with large vessel occlusion. The project addresses the failure of intravenous thrombolysis with tissue plasminogen activator (TPA) to achieve successful recanalization in most eligible patients. Mayo Clinic will conduct three integrated research activities: define metabolic...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Mayo Clinic Arizona $243,678 on December 21, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a multisite longitudinal study characterizing sleep health, sleep disorders, and cognitive functioning in heart transplant recipients. The study will enroll 30 adult heart transplant recipients who are at least six months post-transplant and obtain repeated measures at nine and twelve...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $801,170 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct HOPE: Advancing HFPEF Management Through Evidence-Based Treatment Optimization and Outcome Prediction, a project grant focused on heart failure with preserved ejection fraction. Mayo Clinic will develop therapeutic discovery and biomarker prediction models for HFPEF patients through two integrated research strategies. First, the...
- The National Institute on Aging at the Department of Health and Human Services awarded Mayo Clinic $878,516 in project grant funding on June 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a six-week clinical study examining high-resistance inspiratory muscle strength training as an intervention to reduce sympathetic nerve activity and improve sleep in postmenopausal women experiencing hot flashes. The research addresses vasomotor symptoms associated with menopause, which...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,248 on September 26, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research triangulating causal effects of sleep, inflammation, and cardiometabolic disease. The research will identify oxylipin biomarkers associated with sleep problems—including insomnia, sleep apnea, and short sleep duration—and their relationship to cardiometabolic disease. The study...
- The National Center for Complementary and Integrative Health awarded Mayo Clinic $361,732 on August 28, 2026, under the Research and Training in Complementary and Integrative Health program (CFDA 93.213) to investigate how breathing influences brain activity, perception, and decision-making through brain-body integration research. The project collects a multimodal dataset combining physiological monitoring with advanced human brain recordings. Patients undergoing clinical intracranial EEG...
- The National Institute of Environmental Health Sciences, part of the National Institutes of Health within the Department of Health and Human Services, awarded Mayo Clinic $764,848 on September 9, 2025, under the Medical Library Assistance program (CFDA 93.879) to conduct a multicenter randomized clinical trial of virtual world-based cardiac rehabilitation designed to promote data-powered cardiovascular health among cardiac patients. The project runs through July 31, 2029, with performance at...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $240,600 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to evaluate the combined immunomodulatory effects of macrolides and corticosteroids in hospitalized patients with community-acquired pneumonia. The study investigates how macrolide antibiotics and corticosteroids, often coadministered in community-acquired pneumonia treatment, affect inflammatory markers and clinical outcomes....
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $1,562,026 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a mechanistic and causal inference analysis of propofol-associated hypertriglyceridemia (P-HTG). The research will establish a prospective observational cohort with systematic triglyceride monitoring and comprehensive lipoprotein phenotyping to define P-HTG epidemiology, distinguish clearance-defect from production-excess...
- The National Heart, Lung, and Blood Institute awarded Mayo Clinic $761,573 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a pragmatic, open-label, randomized clinical trial comparing the effectiveness and safety of azithromycin versus doxycycline in combination with beta-lactam therapy for hospitalized adult patients with community-acquired pneumonia. The trial will enroll and randomize 1,120 adult patients hospitalized with community-acquired...